Skip to main content
SpringerLink
Log in

Growth hormone (GH) treatment for Prader-Willi syndrome will be available fully funded for children in New Zealand,

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. PHARMAC.PHARMAC funding growth hormone for Prader-Willi syndrome. Media Release: 3 Oct 2006. Available from: URL: http://www.pharmac.govt.nz

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Growth hormone (GH) treatment for Prader-Willi syndrome will be available fully funded for children in New Zealand,. Pharmacoecon. Outcomes News 514, 10 (2006). https://doi.org/10.2165/00151234-200605140-00028

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605140-00028

Keywords

Search

Navigation